(S)-Laudanosine

(S)-Laudanosine

• CAS Number: 2688-77-9
• UNSPSC Description: (S)-Laudanosine is an alkaloid that can be found in poppies and is the S-enantiomer of Laudanosine. Laudanosine acts on the central nervous system and cardiovascular system, inhibiting low-affinity GABA receptors with an IC50 value of 10 μM, and can cause seizures, hypotension, and bradycardia. Additionally, Laudanosine exerts analgesic effects by competitively binding to the opioid Mu-1 receptor (Ki = 2.7 μM)[1][2][3][4].
• Target Antigen: GABA Receptor; Opioid Receptor
• Type: Natural Products
• Related Pathways: GPCR/G Protein;Membrane Transporter/Ion Channel;Neuronal Signaling
• Field of Research: Neurological Disease; Cardiovascular Disease
• Assay Protocol: https://www.medchemexpress.com/s-laudanosine.html
• Purity: 99.95
• Solubility: DMSO : 50 mg/mL (ultrasonic)
• Smiles: CN1[C@H](C2=C(CC1)C=C(C(OC)=C2)OC)CC3=CC=C(C(OC)=C3)OC
• Molecular Weight: 357.44
• References & Citations: [1]Fodale V, et al. Laudanosine, an atracurium and cisatracurium metabolite[J]. European journal of anaesthesiology, 2002, 19(7): 466-473.|[2]Katz Y, et al. Interactions between laudanosine, GABA, and opioid subtype receptors: implication for laudanosine seizure activity. Brain Res. 1994 May 23;646(2):235-41.|[3]Chuliá S, et al. Mechanism of the cardiovascular activity of laudanosine: comparison with papaverine and other benzylisoquinolines. Br J Pharmacol. 1994 Dec;113(4):1377-85.|[4]Chapple DJ, et al. Cardiovascular and neurological effects of laudanosine. Studies in mice and rats, and in conscious and anaesthetized dogs. Br J Anaesth. 1987 Feb;59(2):218-25.
• Shipping Conditions: Blue Ice
• Storage Conditions: -20°C, 3 years (Powder)
• Clinical Information: No Development Reported